SECsense Logo

Lixte Biotechnology's 8-K Report: Key Stock Insights & Financial Snapshot

$LIXT
Form 8-K
Filed on: 2024-12-20
Source
Lixte Biotechnology's 8-K Report: Key Stock Insights & Financial Snapshot

Here are the key insights and information extracted from the provided financial report section:

  1. Entity Identification:
  • Company Name: Lixte Biotechnology Holdings, Inc.
  • CIK (Central Index Key): 0001335105
  • SEC File Number: 001-39717
  • EIN (Employer Identification Number): 20-2903526
  • Address: 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101
  • Contact Number: (631) 830-7092
  1. Report Type:
  • Filing Type: 8-K (current report)
  1. Date of Filing:
  • Filing Date: December 19, 2024
  1. Stock Information:
  • Common Stock:
    • Par Value: $0.0001 per share
    • Ticker Symbol: LIXT
    • Exchange: NASDAQ
  • Warrants:
    • Par Value: $0.0001 per share
    • Ticker Symbol: LIXTW
    • Exchange: NASDAQ
  1. Reporting Context:
  • The report includes specific references to the common stock and warrants, indicating they are segmented based on their par value and class of stock.
  • The context periods both start and end on December 19, 2024, suggesting that this is a snapshot report for that specific date.
  1. Units of Measurement:
  • The financial report utilizes USD (U.S. Dollars) as the currency measure and shares for stock representation.
  1. Namespace and Formatting:
  • The document uses XBRL (eXtensible Business Reporting Language) formatting, which is common for SEC filings to facilitate automated data extraction.

Insights:

  • The filing is relatively straightforward, focusing on the company's common stock and warrants, which indicates potential activity related to equity financing or stockholder engagement.
  • The use of a par value of $0.0001 suggests a low nominal value for shares, which is common for many biotech firms, reflecting their typical capital structure.
  • Listing on NASDAQ indicates a level of credibility and regulatory compliance, which is important for investor confidence.
  • The specific mention of warrants implies that the company may be considering ways to raise capital or incentivize investment through equity-linked instruments.

This information is crucial for investors, analysts, and stakeholders to assess the company's financial health and strategic direction.